2016
DOI: 10.1016/j.addr.2015.12.001
|View full text |Cite
|
Sign up to set email alerts
|

Advancement in integrin facilitated drug delivery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
88
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 130 publications
(89 citation statements)
references
References 272 publications
1
88
0
Order By: Relevance
“…12 Moreover, integrins are frequently overexpressed in tumour endothelial cells as well as on various tumour cells. Owing to the ability of some integrin subtypes (especially α V β 3 ) to selectively recognize the tripeptide motif -Arg-Gly-Asp-, RGD-containing peptides, particularly the conjugable version of Cilengitide, c(RGDfK), have been used for tumour imaging and for targeted drug delivery of cytotoxic compounds, 13 including metal-based anticancer agents. 14 In recent years, only few examples of caged versions of RGD peptides have been described by modifying the Asp residue 7ce with a photolabile protecting group or by incorporating an o-nitrobenzyl group within the backbone skeleton.…”
Section: Introductionmentioning
confidence: 99%
“…12 Moreover, integrins are frequently overexpressed in tumour endothelial cells as well as on various tumour cells. Owing to the ability of some integrin subtypes (especially α V β 3 ) to selectively recognize the tripeptide motif -Arg-Gly-Asp-, RGD-containing peptides, particularly the conjugable version of Cilengitide, c(RGDfK), have been used for tumour imaging and for targeted drug delivery of cytotoxic compounds, 13 including metal-based anticancer agents. 14 In recent years, only few examples of caged versions of RGD peptides have been described by modifying the Asp residue 7ce with a photolabile protecting group or by incorporating an o-nitrobenzyl group within the backbone skeleton.…”
Section: Introductionmentioning
confidence: 99%
“…Because of the side effect profiles of generic cancer chemotherapeutic agents, there is substantial interest in developing molecular mechanisms that direct these drugs specifically to cancer cells. [6][7][8][9][10][11] Tetraiodothyroacetic acid (tetrac) is a ligand of a specific target on the extracellular domain of plasma membrane integrin αvβ3, 12 an integrin generously expressed by cancer cells and by dividing endothelial cells of tumor-relevant blood vessels. We have covalently bonded tetrac via a short diaminopropane linker to a 150-200 nm poly(lactic-co-glycolic acid) (PLGA) nanoparticle (Nanotetrac, nano-diamino-tetrac [NDAT]), as shown in Figure 1.…”
Section: Introductionmentioning
confidence: 99%
“…Integrins have the ability to recognize multiple ligands and may bind to interaction partners with an RGD sequence (Arg-Gly-Asp), an acidic motif termed "LDV," or a collagenous GFOGER motif. [47][48][49][50][51][52][53] VN, which was identified as a component of the serum corona for dPGS but not for dPGOH NPs, can interact with αvβ3 integrin and could thus possibly be important for the uptake of dPGS NPs as well. [54][55][56] For FBS-treated TiO 2 NPs, it was already shown that cellular uptake into human lung carcinoma cells (A549) was reduced when cells were pre-treated with anti-VN antibodies.…”
mentioning
confidence: 99%